| Collaboration revenue with related party |
The collaboration revenue the Company earned from Sanofi is detailed below: | | | | | | | | | | | | Three Months Ended June 30, | Sanofi Collaboration Revenue | | 2016 | | 2015 | Antibody: | | | | | Reimbursement of Regeneron research and development expenses | | $ | 144,232 |
| | $ | 211,516 |
| Reimbursement of Regeneron commercialization-related expenses | | 85,885 |
| | 27,347 |
| Regeneron's share of losses in connection with commercialization of antibodies | | (122,107 | ) | | (46,313 | ) | Other | | 3,054 |
| | 2,560 |
| Total Antibody | | 111,064 |
| | 195,110 |
| Immuno-oncology: | | | | | Reimbursement of Regeneron research and development expenses | | 32,350 |
| | — |
| Other | | 20,000 |
| | — |
| Total Immuno-oncology | | 52,350 |
| | — |
| | | $ | 163,414 |
| | $ | 195,110 |
|
| | | | | | | | | | | | Six Months Ended June 30, | Sanofi Collaboration Revenue | | 2016 | | 2015 | Antibody: | | | | | Reimbursement of Regeneron research and development expenses | | $ | 337,834 |
| | $ | 380,336 |
| Reimbursement of Regeneron commercialization-related expenses | | 159,159 |
| | 35,805 |
| Regeneron's share of losses in connection with commercialization of antibodies | | (221,529 | ) | | (68,718 | ) | Other | | 6,019 |
| | 5,121 |
| Total Antibody | | 281,483 |
| | 352,544 |
| Immuno-oncology: | | | | | Reimbursement of Regeneron research and development expenses | | 61,625 |
| | — |
| Other | | 40,000 |
| | — |
| Total Immuno-oncology | | 101,625 |
| | — |
| ZALTRAP: | | | | | Reimbursement of Regeneron research and development expenses | | — |
| | 686 |
| Other | | — |
| | 15,236 |
| Total ZALTRAP | | — |
| | 15,922 |
| | | $ | 383,108 |
| | $ | 368,466 |
|
|
| Collaboration revenue |
The collaboration revenue the Company earned from Bayer is detailed below: | | | | | | | | | | | | Three Months Ended June 30, | Bayer Collaboration Revenue | | 2016 | | 2015 | EYLEA: | | | | | Regeneron's net profit in connection with commercialization of EYLEA outside the United States | | $ | 167,492 |
| | $ | 106,631 |
| Cost-sharing of Regeneron EYLEA development expenses | | 2,224 |
| | 2,464 |
| Other | | 13,355 |
| | 16,618 |
| Total EYLEA | | 183,071 |
| | 125,713 |
| PDGFR-beta antibody: | | | | | Cost-sharing of rinucumab/aflibercept (REGN2176-3) development expenses | | 2,762 |
| | 5,926 |
| Other | | 2,607 |
| | 2,598 |
| Total PDGFR-beta | | 5,369 |
| | 8,524 |
| Ang2 antibody: | | | | | Cost-sharing of nesvacumab/aflibercept (REGN910-3) development expenses | | 2,074 |
| | — |
| Other | | 1,382 |
| | — |
| Total Ang2 | | 3,456 |
| | — |
| | | $ | 191,896 |
| | $ | 134,237 |
|
| | | | | | | | | | | | Six Months Ended June 30, | Bayer Collaboration Revenue | | 2016 | | 2015 | EYLEA: | | | | | Regeneron's net profit in connection with commercialization of EYLEA outside the United States | | $ | 313,327 |
| | $ | 196,057 |
| Sales milestones | | — |
| | 15,000 |
| Cost-sharing of Regeneron EYLEA development expenses | | 4,967 |
| | 5,121 |
| Other | | 39,847 |
| | 29,530 |
| Total EYLEA | | 358,141 |
| | 245,708 |
| PDGFR-beta antibody: | | | | | Cost-sharing of rinucumab/aflibercept (REGN2176-3) development expenses | | 4,658 |
| | 7,180 |
| Other | | 5,233 |
| | 5,195 |
| Total PDGFR-beta antibody | | 9,891 |
| | 12,375 |
| Ang2 antibody: | | | | | Cost-sharing of nesvacumab/aflibercept (REGN910-3) development expenses | | 2,074 |
| | — |
| Other | | 1,382 |
| | — |
| Total Ang2 antibody | | 3,456 |
| | — |
| | | $ | 371,488 |
| | $ | 258,083 |
|
|